EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

EUPRAXIA PHARMACEUTICALS INC.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 13, 2026

$6.95+0.33 (+4.98%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

EUPRAXIA PHARMACEUTICALS INC. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	0	0	0	–
Research & Development	21	16	20	14
General & Administrative	17	11	7.48	3.99
Operating Expenses	38	27	28	18
Interest Expense	0	0.60	1.17	0.98
Interest & Investment Income	1.41	1.16	0.86	0.43
Other Non-Operating Income	-0.15	1.26	-1.08	-1.37
Gain (Loss) on Sale of Assets	0.00	0.02	0.00	-0.01
Pretax Income	-39	-26	-29	-19
Income Tax Expense	0.02	0.00	0.04	0
Income from Continuing Operations	-41	-26	-28	–
Net Income incl. Noncontrolling Interests	-39	-26	-29	-19
Minority Interest in Earnings	-0.03	-0.24	-0.75	-0.50
Net Income	-39	-26	-28	-18
Preferred Dividends	2.53	0.43	0	–
EPS (Basic)(per share)	-1.03	-0.76	-1.17	-0.96
EPS (Diluted)(per share)	-1.03	-0.76	-1.17	-0.96
Shares Outstanding (Basic, Weighted)(shares)	40	34	24	19
Shares Outstanding (Diluted, Weighted)(shares)	40	34	24	19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -66.8%

Financial strength

Current ratio: 15.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1431.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –